BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 11264541)

  • 1. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity.
    Nucifora FC; Sasaki M; Peters MF; Huang H; Cooper JK; Yamada M; Takahashi H; Tsuji S; Troncoso J; Dawson VL; Dawson TM; Ross CA
    Science; 2001 Mar; 291(5512):2423-8. PubMed ID: 11264541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice.
    Yu ZX; Li SH; Nguyen HP; Li XJ
    Hum Mol Genet; 2002 Apr; 11(8):905-14. PubMed ID: 11971872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity.
    Bates EA; Victor M; Jones AK; Shi Y; Hart AC
    J Neurosci; 2006 Mar; 26(10):2830-8. PubMed ID: 16525063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin.
    Jiang H; Poirier MA; Liang Y; Pei Z; Weiskittel CE; Smith WW; DeFranco DB; Ross CA
    Neurobiol Dis; 2006 Sep; 23(3):543-51. PubMed ID: 16766198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.
    Dunah AW; Jeong H; Griffin A; Kim YM; Standaert DG; Hersch SM; Mouradian MM; Young AB; Tanese N; Krainc D
    Science; 2002 Jun; 296(5576):2238-43. PubMed ID: 11988536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
    Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
    Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
    Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
    Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CREB-binding protein sequestration by expanded polyglutamine.
    McCampbell A; Taylor JP; Taye AA; Robitschek J; Li M; Walcott J; Merry D; Chai Y; Paulson H; Sobue G; Fischbeck KH
    Hum Mol Genet; 2000 Sep; 9(14):2197-202. PubMed ID: 10958659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment.
    Persichetti F; Trettel F; Huang CC; Fraefel C; Timmers HT; Gusella JF; MacDonald ME
    Neurobiol Dis; 1999 Oct; 6(5):364-75. PubMed ID: 10527804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.
    Truant R; Atwal RS; Burtnik A
    Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant huntingtin represses CBP, but not p300, by binding and protein degradation.
    Cong SY; Pepers BA; Evert BO; Rubinsztein DC; Roos RA; van Ommen GJ; Dorsman JC
    Mol Cell Neurosci; 2005 Sep; 30(1):12-23. PubMed ID: 15994095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular aspects of Huntington's disease.
    Walling HW; Baldassare JJ; Westfall TC
    J Neurosci Res; 1998 Nov; 54(3):301-8. PubMed ID: 9819135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.
    Chaturvedi RK; Hennessey T; Johri A; Tiwari SK; Mishra D; Agarwal S; Kim YS; Beal MF
    Hum Mol Genet; 2012 Aug; 21(15):3474-88. PubMed ID: 22589249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture.
    Cooper JK; Schilling G; Peters MF; Herring WJ; Sharp AH; Kaminsky Z; Masone J; Khan FA; Delanoy M; Borchelt DR; Dawson VL; Dawson TM; Ross CA
    Hum Mol Genet; 1998 May; 7(5):783-90. PubMed ID: 9536081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyglutamine pathogenesis.
    Ross CA; Wood JD; Schilling G; Peters MF; Nucifora FC; Cooper JK; Sharp AH; Margolis RL; Borchelt DR
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1005-11. PubMed ID: 10434299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
    Jana NR; Zemskov EA; Wang Gh ; Nukina N
    Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity.
    Nucifora FC; Ellerby LM; Wellington CL; Wood JD; Herring WJ; Sawa A; Hayden MR; Dawson VL; Dawson TM; Ross CA
    J Biol Chem; 2003 Apr; 278(15):13047-55. PubMed ID: 12464607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of overexpression of huntingtin proteins on mitochondrial integrity.
    Wang H; Lim PJ; Karbowski M; Monteiro MJ
    Hum Mol Genet; 2009 Feb; 18(4):737-52. PubMed ID: 19039036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells.
    Chun W; Lesort M; Tucholski J; Faber PW; MacDonald ME; Ross CA; Johnson GV
    Neurobiol Dis; 2001 Jun; 8(3):391-404. PubMed ID: 11442349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomedicine. Huntingtin--profit and loss.
    Trottier Y; Mandel JL
    Science; 2001 Jul; 293(5529):445-6. PubMed ID: 11463904
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.